Atrion's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Atrion (ATRI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Atrion vs Its Competitors
- TTM: Trailing 12-month revenue of 182M vs 142,204M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.4% annualized vs trailing 12 months), vs decelerating (-9.2%) for its tracked peer group.
- Growth: Atrion generated 11.3% revenue growth year over year in Q2 2024, vs 4.8% for its tracked competitors combined.
- Profitability: Its 0.8% net margin compares with 8.9% for the peer group.
- Peer revenue share: Atrion accounted for 0.2% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $0.36M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATRI Sales vs. its Competitors, Q2 2024
Atrion reported revenue growth of 11.26 % year on year in Q2 2024, above its competitors' combined revenue growth of 4.79 %.
With a net margin of 0.82 %, Atrion reported lower profitability than its competitors (8.90 %).
Atrion generated 0.15 % of the combined sales of its peer group, up from 0.14 % a year earlier.
Atrion vs. its Competitors, Q2 2024
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Atrion and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Atrion Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Atrion's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.1% year over year, combined, vs 11.3% for Atrion. Atrion's share of combined industry revenue moved from 0.04% to 0.04%, a gain of 0.00 percentage points.
Atrion's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Atrion Corporation | Yes | Yes | No | No |
| Competitors combined (42) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 87.50 % (7 of 8) | 37.50 % (3 of 8) | 0.00 % (0 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATRI Stock Performance relative to its Competitors
ATRI Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Vaso Corporation | 282.9% | Outperformed |
| 2 | Orchestra Biomed Holdings Inc | 282.9% | Outperformed |
| 3 | Atricure Inc | 282.9% | Outperformed |
| 4 | Livanova Plc | 282.9% | Outperformed |
| 5 | Angiodynamics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Atrion's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Atrion's Comment on Competition and Industry Peers
Publicly Traded Peers of Atrion Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Atrion Corporation | 810.84 | 181.60 |
| Medtronic Plc | 111,533.83 | 37,542.00 |
| Stryker Corp | 106,026.48 | 25,837.00 |
| Boston Scientific Corporation | 64,124.30 | 20,997.00 |
| Becton Dickinson And Company | 49,943.93 | 20,840.00 |
| Edwards Lifesciences Corporation | 49,806.45 | 6,512.50 |
| SUBTOTAL | 485,948.62 | 144,812.26 |
Sign in to see all competitors of Atrion Corporation.
Sources: Atrion Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Atrion Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Atrion's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ultimate Products Corp | Named by the company | 85% |
| Merit Medical Systems Inc | Named by the company | 85% |
| Utah Medical Products Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Atrion's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Atrion's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
| Edwards Lifesciences Corporation | United States 57.64 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Atrion Corporation.
Atrion's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Atrion Corporation | 811 | 255,059 | 17,636 |
| Medtronic Plc | 111,534 | 395,179 | 55,463 |
| Stryker Corp | 106,026 | 461,375 | 66,589 |
| Boston Scientific Corporation | 64,124 | 355,881 | 62,186 |
| Becton Dickinson And Company | 49,944 | 289,444 | 13,069 |
| Edwards Lifesciences Corporation | 49,806 | 407,031 | 62,725 |
| PEERS TOTAL | 485,138 | 363,847 | 33,218 |
Sign in to see all peers for Atrion Corporation.
Atrion's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Atrion Corporation | United State 63.19 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
| Becton Dickinson And Company | United States 61.88 % |
| Abiomed Inc | United States 82.33 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Atrion Corporation.
Atrion's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 32.59 % | 53.36 % (avg) | -20.8 pp |
| Operating Margin | -4.49 % | industry median | +8.1 pp |
| EBITDA Margin | 8.14 % | -6.79 % (avg) | +14.9 pp |
| Capital Intensity (Capex / Revenue) | 9.73 % | 5.43 % (avg) | +4.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Atrion's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 63.4x | 34.6x | +28.8x |
| EV / EBITDA | 54.1x | 19.7x | +34.5x |
| P/B | 3.3x | 4.7x | -1.4x |
| Return on Equity | 5.21 % | industry aggregate | -2.10 % |
| Return on Invested Capital | -1.68 % | -2.30 % (avg) | 0.62 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Atrion's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 3.53 % | -1.54 % | 2.17 % | 3.99 % | 1.72 % | 3.51 % | 11.21 % | -7.73 % |
| Operating Margin | 29.17 % | 27.27 % | 28.16 % | 27.36 % | 26.14 % | 26.14 % | 21.63 % | 0.01 % |
| Return on Invested Capital | 14.52 % | 12.12 % | 11.41 % | 10.10 % | 8.63 % | 8.15 % | 8.01 % | 0.00 % |
| P/E | 24.3x | 32.3x | 31.9x | 40.1x | 36.9x | 35.9x | 31.3x | 30.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Atrion's Strategic Group Map
Every company in Atrion's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Atrion is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Atrion's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 9.73 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Atrion's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Atrion's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Atrion's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Atrion falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Atrion's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 8.1 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+7.4% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.2% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Atrion's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Atrion Corporation | 0.12 | 8.02 | 0.03 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
| Becton Dickinson And Company | 0.10 | 1.00 | 0.73 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
Sign in to see all peers for Atrion Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Atrion's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Atrion Corporation | Q2 2024 | +11.3 % | -93.9 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| Becton Dickinson And Company | Q2 2026 | +5.4 % | -34.3 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| PEERS TOTAL | +8.6 % | +39.3 % |
Sign in to see all peers for Atrion Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Atrion's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Atrion Corporation | Q2 2024 | +23.9 % | -75.1 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
| Becton Dickinson And Company | Q2 2026 | +7.1 % | -12.8 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
Sign in to see all peers for Atrion Corporation.
Atrion's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Atrion Corporation | 4.81% | 5.14% | 5.21% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
| Becton Dickinson And Company | 1.77% | 2.22% | 3.79% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
Sign in to see all peers for Atrion Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Atrion's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Atrion Corporation | 64.41 | 4.46 |
| Medtronic Plc | 255.26 | 2.97 |
| Stryker Corp | 28.46 | 4.10 |
| Boston Scientific Corporation | 17.63 | 3.05 |
| Becton Dickinson And Company | 54.84 | 2.40 |
| Edwards Lifesciences Corporation | 49.64 | 7.65 |
| PEERS AVERAGE | 36.77 | 3.36 |
Sign in to see all peers for Atrion Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.